TCF19 contributes to cell proliferation of non‐small cell lung cancer by inhibiting FOXO1

Abstract

Transcription factor 19 (TCF19) harbors a forkhead association (FHA) domain, a proline-rich region, a PHD or RING finger region, suggesting that TCF19 possesses a powerful function. However, its expression and function remains unknown in non-small-cell lung cancer (NSCLC). The function cluster analysis was carried out using Metascape website. 3-(4,5-Dimethyl-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide (MTT), colony formation, and anchorage-independent growth ability assay were carried out to detect the effect of TCF19 on cell proliferation. Bromodeoxyuridine (Brdu) labeling and flow cytometry assay were used to evaluate the effect of TCF19 on cell-cycle progression. Quantitative polymerase chain reaction and chromatin immunoprecipitation assay were performed to investigate the mechanism by which TCF19 is involved in cell-cycle transition. By analyzing the publicly available dataset, The Cancer Genome Atlas (TCGA), we found that TCF19 is significantly increased in the lung adenocarcinoma (LAC) and squamous cell carcinoma (SCC), two primary histological subtype of NSCLC. Besides, further function cluster analysis exhibited that TCF19 may mainly participate in cell cycle. MTT, colony formation, and anchorage-independent growth ability assay confirmed that overexpression of TCF19 enhances the proliferation of both LAC and SCC cells. Besides, further experiments revealed that TCF19 contributes to cell cycle G1/S transition. Not only that, upregulation of TCF19 can inhibit the expression of p21, p27, and p57, while promote the expression of cyclin D1 by inhibiting FOXO1. Our research offers important evidence that TCF19 can promote cell-cycle progression of NSCLC cells, and TCF19 may served as novel therapeutic targets.

<p>LncRNA MIR194-2HG Promotes Cell Proliferation and Metastasis via Regulation of miR-1207-5p/TCF19/Wnt/β-Catenin Signaling in Liver Cancer</p>

“…Several studies have reported that TCF19 played an oncogenic role in cancers. [22][23][24] Herein, we also demonstrated that TCF19 promoted cell proliferation in liver cancer by MTT assay and colony formation assay ( Figure 6A-C), which was consistent with the demonstrations in the previous report. 22 However, whether TCF19 also affected the migration and invasion abilities of liver cancer cells was unreported.…”

“…[19][20][21]35,36 However, a lncRNA PVT1-induced microRNA, miR-1207-5p, has been reported to promote growth by directly suppressing STAT6 in breast cancer cells. 37 Subsequently, we demonstrated that miR-1207-5p directly inhibited the expression of TCF19, a newly identified target of miR-1207-5p, that could play an oncogenic role in several cancers, such as colorectal cancer, 23 non-small cell lung cancer, 24 and liver cancer. 22,38 Consistent with the findings of previous studies, 22,38 we demonstrated that TCF19 promoted cell proliferation in HCC.…”

COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types

“…1a). TCF19 encodes for a transcription factor TCF19 that has been shown to regulate activation of T cells 21 and also involved in cell proliferation 22,23 . A noteworthy example of a highly cell-specific severe COVID-19-risk eGene in regulatory T cells (TREG) was PDE4A (Extended Data Fig.…”

Identification of novel genes associated with diagnosis and prognosis in glioblastoma

“…There were no reports of the expression level of THBD in brain tumors, our study showed that THBD was highly expressed in GBM patients, and patients with different expression levels had inequable prognosis. Finally, several studies had found that in non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer TCF19 (transcription factor 19) could promote cell proliferation and increase tumor invasiveness through some pathways, but there were no reports about its role in GBM [33][34][35][36]. Our study found that TCF19 was highly expressed in GBM patients, and patients with different expression levels also had inequable prognosis.…”